Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders.
Saved in:
| Title: | Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders. |
|---|---|
| Authors: | Strober, Bruce1 (AUTHOR), Armstrong, April2 (AUTHOR), Rubant, Simone3 (AUTHOR), Patel, Manish3 (AUTHOR), Wu, Tianshuang3 (AUTHOR), Photowala, Huzefa3 (AUTHOR), Crowley, Jeffrey4 (AUTHOR) |
| Source: | Journal of Dermatological Treatment. Nov2022, Vol. 33 Issue 7, p2991-2996. 6p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
